Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products globally. Its portfolio includes treatments for narcolepsy, idiopathic hypersomnia, epilepsy, and certain cancers. Key products include Xywav for cataplexy or excessive daytime sleepiness associated with narcolepsy and idiopathic hypersomnia; Epidiolex for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex; Rylaze and Enrylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Zepzelca for metastatic small cell lung cancer; Ziihera for HER2-positive biliary tract cancers; Modeyso for diffuse midline glioma; and Defitelio for severe veno-occlusive disease. The company also has a pipeline including Zanidatamab in Phase 3 trials for HER2-positive gastroesophageal adenocarcinoma and biliary tract cancers, and other early-stage candidates.

Jazz Pharmaceuticals plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol JAZZ. Its shares trade in US Dollars (USD). The company is incorporated in Ireland and is part of the US region for reporting purposes, but its stock is primarily traded on the US-based Nasdaq exchange.

Jazz Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on identifying, developing, and commercializing innovative pharmaceutical products for a range of therapeutic areas, including sleep disorders, epilepsy, oncology, and rare diseases. The company's products address significant unmet medical needs, such as narcolepsy, certain seizure disorders, and various cancers.

Jazz Pharmaceuticals has a substantial oncology portfolio. Key products include Rylaze and Enrylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Zepzelca for metastatic small cell lung cancer after platinum-based chemotherapy; Ziihera for HER2-positive biliary tract cancers; Modeyso for diffuse midline glioma with an H3 K27M mutation; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. The company is also developing Zanidatamab in Phase 3 trials for HER2-positive gastroesophageal adenocarcinoma and biliary tract cancers, and for neoadjuvant and adjuvant breast cancer. Additionally, it has early-stage candidates like JZP815 targeting Raf and Ra pathways.